Guided Therapeutics (GTHP) Net Cash Flow Growth (3y) (2014 - 2026)
Guided Therapeutics (GTHP) Net Cash Flow Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 269.22% |
| 10 | Guided Therapeutics | 21.24 Mn | 21.23 Mn | - | 9.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.33% |
| Mar 31, 2026 | 38.26% |
| Dec 31, 2025 | 60.31% |
| Sep 30, 2025 | -26.88% |
| Jun 30, 2025 | 31.37% |
| Mar 31, 2025 | -74.67% |
| Dec 31, 2024 | 23.90% |
| Sep 30, 2024 | 40.32% |
| Jun 30, 2024 | 19.43% |
| Mar 31, 2024 | -28.81% |
| Dec 31, 2023 | 29.47% |
| Sep 30, 2023 | -50.76% |
| Jun 30, 2023 | -38.29% |
| Mar 31, 2023 | 18.46% |
| Dec 31, 2022 | -34.39% |
| Jun 30, 2022 | -252.14% |
| Mar 31, 2022 | 139.09% |
| Dec 31, 2021 | 51.21% |
| Sep 30, 2021 | -147.37% |
| Jun 30, 2021 | -110.19% |